Form 4: Lilly Endowment Inc. Sells Shares of Eli Lilly & Co in Multiple Transactions
SEC Form 4 Filing
Lilly Endowment Inc. sold a total of 34,538 shares of Eli Lilly & Co. common stock in multiple transactions on January 9, 2024, at weighted average prices ranging from $630.389 to $633.41.
Summary
- Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co., executed multiple sales of common stock on January 9, 2024.
- The sales were conducted in four separate transactions at varying weighted average prices.
- A total of 34,538 shares were sold, reducing Lilly Endowment's holdings to 99,719,884 shares.
- The weighted average prices for the transactions ranged from $630.389 to $633.41 per share.
- The transactions were executed under the SEC's Form 4 guidelines, which require disclosure of changes in beneficial ownership.
Sentiment
Score: 5
Explanation: The document is a neutral report of a stock sale, with no indication of positive or negative sentiment. It is a routine filing.
Industry Context
This filing reflects a routine transaction by a major shareholder and is not indicative of any specific industry trend or competitive shift. It is a standard disclosure required by the SEC for significant changes in beneficial ownership.
Comparison to Industry Standards
- Form 4 filings are a standard practice for reporting changes in beneficial ownership by insiders and major shareholders in publicly traded companies.
- The transactions are typical for large institutional investors managing their portfolios.
- The volume of shares sold is not unusual for a large shareholder like Lilly Endowment Inc.
Stakeholder Impact
- The sale of shares by Lilly Endowment Inc. may have a minor impact on the stock price of Eli Lilly & Co., but is unlikely to be significant given the relatively small volume of shares sold compared to the total outstanding shares.
- The transaction does not directly impact employees, customers, or suppliers.
Key Dates
| Date | Description |
|---|---|
| 01/09/2024 | Date of the stock sale transactions by Lilly Endowment Inc. |
| 01/10/2024 | Date the SEC Form 4 was signed and filed. |
Keywords
Eli Lilly & Co, Lilly Endowment Inc, stock sale, share transaction, beneficial ownership, SEC Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.